Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception

AIDS

Volumn 25, Issue 13, 2011, Pages 1647-1655

  Huntington, Susie E ^a,b   Bansi, Loveleen K ^a   Thorne, Claire ^b   Anderson, Jane ^c   Newell, Marie Louise ^b,d   Taylor, Graham P ^e   Pillay, Deenan ^a,f   Hill, Teresa ^a   Tookey, Pat A ^b   Sabin, Caroline A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e ST MARY S HOSPITAL   (United States)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

antiretroviral agents; antiretroviral therapy; HIV; pregnancy; United Kingdom

Indexed keywords

DIDANOSINE; EFAVIRENZ;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MATERNAL DISEASE; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PRIORITY JOURNAL; SUBSTITUTION THERAPY; TREATMENT OUTCOME; UNITED KINGDOM; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; FERTILIZATION; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 80051792960     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834982af     Document Type: Article

References (26)

1. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. BJOG 2008;115:1078-1086. (Pubitemid 352000353)
2. National Study of HIV in Pregnancy and Childhood. Obstetric and paediatric HIV surveillance data from the UK and Ireland. NSHPC update; September 2010. www.nshpc.ucl.ac.uk/slides/NSHPC-slides-Q84-protected.ppt [Last Accessed December 2010].
3. de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008;9:452-502.
4. Gazzard B, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608.
5. US Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States (Updated 8 July 2008). http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. [Accessed January 2011].
6. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16:299-300. (Pubitemid 34118582)
7. de Santis M, Carducci B, De Santis L, Cavaliere A, Straface G. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 2002;162:355. (Pubitemid 34127415)
8. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report, December 2010. Wilmington, NC: Registry Coordinating Centre; 2010. www.apregistry.com/forms/interim-report.pdf [Last accessed May 2011].
9. Ford N, Mofenson L, Kranzer K, Medue L, Frigatif L, Mills EJ, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010;24:1461-1470.
10. Townsend C, Willey B, Cortina-Borja M, Peckham C, Tookey P. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009;23:519-524.
11. Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, Messou E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Adidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2011;56:183-187.
12. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004;5:115-124.
13. Townsend C, Schulte J, Thorne C, Dominguez KL, Tookey PA, Cortina-Borja M, et al. Antiretroviral therapy and preterm delivery: a pooled analysis of data from the United States. BJOG 2010;117:1399-1410.
14. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22:973-981. (Pubitemid 351652248)
15. Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS 2009;23:513-520.
16. Floridia M, Tamburrini E, Ravizza M, Anzidei G, Tibaldi C, Bucceri A, et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther 2006;11:941-946. (Pubitemid 44736187)
17. Hsu H, Rydzak C, Cotich K, Wang B, Sax P, Losina E, et al. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med 2011;12:97-108.
18. Fiore S, Heard I, Thorne C, Savasi V, Coll O, Malyuta R, et al. Reproductive experience of HIV-infected women living in Europe. Hum Reprod 2008;23:2140-2144.
19. Floridia M, Tamburrini E, Bucceri A, Tibaldi C, Anzidei G, Guaraldi G, et al. Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationality. BJOG 2007;114:896-900. (Pubitemid 46918693)
20. Thorne C, Patel D, Fiore S, Peckham C, Newell ML; European collaborative study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-465. (Pubitemid 40216516)
21. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-494. (Pubitemid 34456340)
22. Patel D, Cortina-Borja M, De Maria A, Newell ML, Thorne C. Factors associated with HIV RNA levels in pregnant women on nonsuppressive highly active antiretroviral therapy at conception. Antivir Ther 2010;15:41-49.
23. United Kingdom Collaborative HIV Cohort Study, Lee KJ, Dunn D, Gilson R, Porter K, Bansi L, Hill T, et al. Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS 2008;22:1943-1950.
24. Bardequez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr 2008;48:408-417.
25. Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 2008;20:958-968.
26. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, Abrams EJ. Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in sub-Saharan Africa: a cohort study. PloS Med 2010;7:e1000229.